

CHEMOTHERAPY FOR GYNECOLOGIC CANCERS:

Society of Gynecologic Oncology Handbook
Third Edition

Join our pre-order list for exclusive savings:
bit.ly/chemohandbook

Editors

Christina M. Annunziata, MD, PhD

Principal Investigator and Clinical Director
Women's Malignancies Branch
National Cancer Institute, Bethesda, MD

Christina S. Chu, MD

Associate Professor, Gynecologic Oncology
Director, Gynecologic Oncology Fellowship Program
Department of Surgical Oncology
Division of Gynecologic Oncology
Fox Chase Cancer Center, Philadelphia, PA

Stephen C. Rubin, MD

Professor and Chief
Division of Gynecologic Oncology
Grotzinger-Raab Chair in Surgical Oncology
Fox Chase Cancer Center, Philadelphia, PA

With 25 Contributors



Society of Gynecologic Oncology

Preface to the Third Edition

The third edition of the *Chemotherapy of Gynecologic Cancers* details the tremendous advances that have been made in the medical management of gynecologic cancers since the prior edition. In ovarian cancer, major clinical trials have helped to define the role of dose-dense chemotherapy, anti-angiogenesis agents, intraperitoneal chemotherapy, and maintenance therapies. New chemotherapy regimens are in use for endometrial cancer, and particularly exciting is the development of effective systemic treatment for advanced and recurrent cervical cancer.

The entire book has been extensively updated, and multiple new chapters have been added, such as individual chapters on the role of chemotherapy in the major gynecologic cancer sites, including gestational trophoblastic disease (GTD). A new chapter has also been added on targeted therapies, which are assuming an increasingly important role in the management of gynecologic cancers. The chapters on chemotherapy premedication, and the management of both hematologic and non-hematologic toxicities have been rewritten, and a new chapter has been added on care of the cancer patient near the end of life.

It is the editors' hope that this third edition, which has been authored by an outstanding group of experts in the field, will continue to serve as a concise, clinically useful reference to practitioners in their everyday care of women with gynecologic cancers.

Table of Contents

Chapter 1: Introduction and Principles of Chemotherapy

Kimberly S. Strickland, MD, Jennifer M. Johnson, MD and Russell J. Schilder, MD

- Brief history of the development of chemotherapy
- Principles of combination chemotherapy
- Overview of chemotherapy toxicity

Chapter 2: Chemotherapeutic Agents Used in the Treatment of Gynecologic Malignancies

Elise C. Kohn, MD, Linda R. Duska, MD, MPH, Sarah M. Temkin, MD and S. Percy Ivy, MD

- Focus on frequently used agents
- Emphasis is placed on developing a rationale for appropriate usage

Chapter 3: Targeted Therapy for Gynecologic Malignancies

Krishnansu S. Tewari, MD and Robert A. Burger, MD

- Focuses on recent progress in anti-angiogenesis therapy, PARP inhibition, and immunotherapy
- Includes discussion of investigational therapies

Chapter 4: Design of Clinical Trials

Thomas J. Herzog, MD and Mark F. Brady, MD

- Traditional concepts for trial design and concepts presented
- Definitions of Phase I, II, and III trials
- Differentiation between prognostic and predictive biomarkers

Chapter 5: Role of Chemotherapy in Epithelial Cancers of the Ovary, Fallopian Tube, Peritoneum

Maurie Markman, MD

- Description of specific regimens
- Discussion of chemotherapy for high risk early stage ovarian cancer, second-line (and beyond), recurrent, potentially platinum-sensitive versus platinum-resistant ovarian cancer
- Thorough review of targeted therapy of ovarian cancer

Chapter 6: Role of Chemotherapy in Non-Epithelial Ovarian Cancers

Jennifer I. Brown, MD and Gina M. Mantia-Smaldone, MD

- Roles of surgery and systemic chemotherapy for each cancer
- Overview of recurrence therapy, adverse effects, protocols, prognosis
- Surveillance of each disease

Chapter 7: Role of Chemotherapy in Cancers of the Uterus

Andrea R. Hagemann, MD and Carolyn K. McCourt, MD

- Reviews the use of systemic therapy in the full range of corpus cancers
- Development of current chemotherapy regimens
- Role of anti-angiogenic agents, hormonal therapy, and targeted therapies

Chapter 8: Role of Chemotherapy in Cancers of the Cervix, Vagina, and Vulva

Jonathan A. Cosin, MD and Jason A. Konner, MD

- Reviews systemic treatment of early stage disease, locally advanced disease, and recurrent disease
- New FIGO staging is detailed
- Chemotherapy options discussed in detail

Chapter 9: Role of Chemotherapy in Gestational Trophoblastic Disease

Emese Zsiros, MD, PhD and Julian C. Schink, MD

- Detailed overview of the major clinicopathologic forms of GTD
- Evaluation and follow up of patients with molar pregnancies
- Treatment and follow up for low-risk and high-risk GTN is reviewed

Chapter 10: Premedications, Antiemetics, and other Considerations in Antineoplastic Therapy

I. Daniel Benrubi, MD, MPH and Christina S. Chu, MD

- Focuses on methods to minimize the severity of nausea and emesis, renal and urinary tract toxicity, and hypersensitivity reactions to chemotherapy

Chapter 11: Management of Hematologic Toxicities

John B. Liao, MD, PhD

- Covers the evaluation and management of neutropenic fever, anemia, thrombocytopenia and coagulopathy
- Growth factors are reviewed with their correlated dosage, administration and toxicities listed
- Administration and complications of transfusion of blood components are presented

Chapter 12: Management of Non-Hematologic Toxicities and Complications

Megan F. Peterson, MSN, WHNP-C and Joanne K. Rash, MPAS, PA-C

- Reviews six toxicities with supplemental tables for quick review and reference
- Includes Hypersensitivity Reactions; Extravasation of Irritants and Vesicants; Mucositis; Chemotherapy-Induced Peripheral Neuropathy (CIPN); Palmar-plantar Erythrodysesthesia Syndrome PPE (hand-foot syndrome); Central Venous Catheter

Chapter 13: Care of the Cancer Patient near the End of Life

Christopher V. Lutman, MD

- Defines palliative anti-cancer medications
- Emphasizes the importance of prognostication and communication, while referencing the palliative prognostic Index and the SPIKES protocol

Appendices

Definitions of Response (RECIST)

Performance Status

Common Toxicity Criteria (CTC)

Chemotherapy Calculations